[Advances in Gene Therapy for Inborn Errors of Immunity]

Overview

Journal Zhongguo Dang Dai Er Ke Za Zhi

Specialty Pediatrics

Date 2024 Aug 16

PMID 39148393

Authors

Ting Li

Hong-Mei Song

Affiliations

Soon will be listed here.

Abstract

Inborn errors of immunity (IEI) are a diverse group of disorders caused by defects in immune system structure or function, involving both innate and adaptive immunity. The 2022 update of the IEI classification includes 485 distinct disorders, categorized into ten major disease groups. With the rapid development of molecular biology, the specific pathogenesis of many IEI has been revealed, making gene therapy possible in preclinical and clinical research of this type of disease. This article reviews the advancements in gene therapy for IEI, aiming to increase awareness and understanding of these disorders.

References

Dogbey D, Torres V, Fajemisin E, Mpondo L, Ngwenya T, Akinrinmade O . Technological advances in the use of viral and non-viral vectors for delivering genetic and non-genetic cargos for cancer therapy. Drug Deliv Transl Res. 2023; 13(11):2719-2738. PMC: 10257536. DOI: 10.1007/s13346-023-01362-3. View

Cowan M, Yu J, Facchino J, Fraser-Browne C, Sanford U, Kawahara M . Lentiviral Gene Therapy for Artemis-Deficient SCID. N Engl J Med. 2022; 387(25):2344-2355. PMC: 9884487. DOI: 10.1056/NEJMoa2206575. View

Pai S, Thrasher A . Gene therapy for X-linked severe combined immunodeficiency: Historical outcomes and current status. J Allergy Clin Immunol. 2020; 146(2):258-261. DOI: 10.1016/j.jaci.2020.05.055. View

Bulcha J, Wang Y, Ma H, Tai P, Gao G . Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021; 6(1):53. PMC: 7868676. DOI: 10.1038/s41392-021-00487-6. View

Lee P, Davidson B, Abraham R, Alter B, Arostegui J, Bell K . Evaluation and Management of Deficiency of Adenosine Deaminase 2: An International Consensus Statement. JAMA Netw Open. 2023; 6(5):e2315894. DOI: 10.1001/jamanetworkopen.2023.15894. View

Cavazzana M, Thrasher A . Gene therapy for Whiskott-Aldrich syndrome: The latest news. Clin Transl Med. 2022; 12(4):e815. PMC: 9016166. DOI: 10.1002/ctm2.815. View

Pai S, Logan B, Griffith L, Buckley R, Parrott R, Dvorak C . Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med. 2014; 371(5):434-46. PMC: 4183064. DOI: 10.1056/NEJMoa1401177. View

Hashem H, Dimitrova D, Meyts I . Allogeneic Hematopoietic Cell Transplantation for Patients With Deficiency of Adenosine Deaminase 2 (DADA2): Approaches, Obstacles and Special Considerations. Front Immunol. 2022; 13:932385. PMC: 9336546. DOI: 10.3389/fimmu.2022.932385. View

Ginn S, Amaya A, Alexander I, Edelstein M, Abedi M . Gene therapy clinical trials worldwide to 2017: An update. J Gene Med. 2018; 20(5):e3015. DOI: 10.1002/jgm.3015. View

10.

Fischer A . Gene therapy for inborn errors of immunity: past, present and future. Nat Rev Immunol. 2022; 23(6):397-408. DOI: 10.1038/s41577-022-00800-6. View

11.

Rai R, Romito M, Rivers E, Turchiano G, Blattner G, Vetharoy W . Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott - Aldrich Syndrome. Nat Commun. 2020; 11(1):4034. PMC: 7423939. DOI: 10.1038/s41467-020-17626-2. View

12.

Laskowski T, Van Caeneghem Y, Pourebrahim R, Ma C, Ni Z, Garate Z . Gene Correction of iPSCs from a Wiskott-Aldrich Syndrome Patient Normalizes the Lymphoid Developmental and Functional Defects. Stem Cell Reports. 2016; 7(2):139-48. PMC: 4982969. DOI: 10.1016/j.stemcr.2016.06.003. View

13.

Labrosse R, Chu J, Armant M, Everett J, Pellin D, Kareddy N . Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Blood. 2023; 142(15):1281-1296. PMC: 10731922. DOI: 10.1182/blood.2022019117. View

14.

Azarnezhad A, Samadian H, Jaymand M, Sobhani M, Ahmadi A . Toxicological profile of lipid-based nanostructures: are they considered as completely safe nanocarriers?. Crit Rev Toxicol. 2020; 50(2):148-176. DOI: 10.1080/10408444.2020.1719974. View

15.

Ott de Bruin L, Lankester A, Staal F . Advances in gene therapy for inborn errors of immunity. Curr Opin Allergy Clin Immunol. 2023; 23(6):467-477. PMC: 10621649. DOI: 10.1097/ACI.0000000000000952. View

16.

Zoccolillo M, Brigida I, Barzaghi F, Scala S, Hernandez R, Basso-Ricci L . Lentiviral correction of enzymatic activity restrains macrophage inflammation in adenosine deaminase 2 deficiency. Blood Adv. 2021; 5(16):3174-3187. PMC: 8405196. DOI: 10.1182/bloodadvances.2020003811. View

17.

Castiello M, Ferrari S, Villa A . Correcting inborn errors of immunity: From viral mediated gene addition to gene editing. Semin Immunol. 2023; 66:101731. PMC: 10109147. DOI: 10.1016/j.smim.2023.101731. View

18.

Kavanagh H, Dunne S, Martin D, McFadden E, Gallagher L, Schwaber J . A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy applications. Cytotherapy. 2021; 23(9):852-860. PMC: 8386197. DOI: 10.1016/j.jcyt.2021.03.002. View

19.

Vieira R, Pinho L, Westerberg L . Understanding immunoactinopathies: A decade of research on WAS gene defects. Pediatr Allergy Immunol. 2023; 34(4):e13951. DOI: 10.1111/pai.13951. View

20.

Tucci F, Galimberti S, Naldini L, Valsecchi M, Aiuti A . A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders. Nat Commun. 2022; 13(1):1315. PMC: 8921234. DOI: 10.1038/s41467-022-28762-2. View